LTR Pharma Limited (ASX:LTP)

Australia flag Australia · Delayed Price · Currency is AUD
0.2900
+0.0100 (3.57%)
At close: Jul 14, 2025, 4:00 PM AEST
Market Cap 57.91M
Revenue (ttm) 499.71K
Net Income (ttm) -6.82M
Shares Out 180.98M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,507
Average Volume 146,385
Open 0.2850
Previous Close 0.2800
Day's Range 0.2850 - 0.2950
52-Week Range 0.2700 - 2.1600
Beta n/a
RSI 54.79
Earnings Date Aug 29, 2025

About LTR Pharma

LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LTP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.